EverSource Wealth Advisors’s Basel Medical BMGL Stock Holding History

EverSource Wealth Advisors’s Portfolio BMGL Stock Details BMGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-23	Closed	-$504	–	4498
2025 Q3	$504	Buy	+23	New	+$577	﹤0.01%	3948

Other funds holding BMGL

GSC

Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BIA

Bell Investment Advisors Oakland, California $639M AUM 13.28% 1-Year Est. Return

EverSource Wealth Advisors's BMGL Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Basel Medical (BMGL) in Q4 2025, closing a stake of 23 shares — an estimated $504 sold.

EverSource Wealth Advisors first reported a position in BMGL in Q3 2025 and held it in 1 quarter. The position peaked at $504 in Q3 2025. 9 funds tracked by Wall St. Rank hold BMGL as of Q4 2025.

EverSource Wealth Advisors reported no remaining Basel Medical position as of Q4 2025 after selling out during the quarter.
EverSource Wealth Advisors sold 23 Basel Medical shares in Q4 2025, an estimated $504.
EverSource Wealth Advisors first reported a position in Basel Medical in Q3 2025 and held it in 1 quarter.
EverSource Wealth Advisors's Basel Medical position peaked at $504 in Q3 2025.
9 funds tracked by Wall St. Rank held Basel Medical as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.